Lentinan
 | |
| IUPACime | |
|---|---|
β-D-glukopiranozil-(1→6)-[β-D-glukopiranozil-(1→3)-[β-D-glukopiranozil-(1→6)]-β-D-glukopiranozil-(1→3)-β-D-glukopiranozil-(1→3)β-D-glukopiranozil-(1→3)]-β-D-glukopiranoza | |
| Klinički podaci | |
| Drugs.com | Internacionalno ime leka |
| Identifikatori | |
| CAS broj | 37339-90-5 |
| ATC kod | L03AX01(WHO) |
| PubChem | CID37723 |
| KEGG | D01695 |
| Sinonimi | (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol |
| Hemijski podaci | |
| Formula | C42H72O36 |
| Molarna masa | 1152.99948 g/mol |
Lentinanjebeta-glukansa glikozidnim β-1,3:β-1,6 vezama.[1]On je antitumornipolisaharidizšitake(Lentinula edodes) pečurke.[1]Lentinan je polisaharid sa molekulskom težinom od oko 500.000 Da. Japanska farmaceutska kompanijaAjinomotoje razvila lek Lentinan, koji se intravenozno dozira kao agens protiv kancera.[2]
Lentinan je jedan od lekova protiv kancera[3]za koji je pokazano da utiče na odbrambeni imunski sistem domaćina.[4]
Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.[5][6][7][8][9][10][11][12]
Vidi još
[уреди|уреди извор]Reference
[уреди|уреди извор]- ^абCancer GuideАрхивиранона сајтуWayback Machine(31. децембар 2012) Includes many abstracts
- ^„Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments”.
- ^Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”.Hepatogastroenterology.46(28): 2662—8.PMID10522061.
- ^Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”.Hepatogastroenterology.46(28): 2662—8.PMID10522061.
- ^ Yang P; Liang M; Zhang Y; Shen B. (2008). „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”.Adv Ther.25(8): 787—94.PMID18670743.doi:10.1007/s12325-008-0079-x.
- ^ Nimura H, Mitsumori N, Takahashi N (2006). „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”.Gan to Kagaku Ryoho.33(1): 106—9.PMID16897983.
- ^ Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K. (1999). „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”.Hepatogastroenterology.46(28): 2662—8.PMID10522061.
- ^Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2009). „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”.Anticancer Res.29(7): 2739—45.PMID19596954.
- ^Hazama S; Watanabe S; Ohashi M; et al. (2009). „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”.Anticancer Res.29(7): 2611—7.PMID19596936.
- ^Kataoka H; Shimura T; Mizoshita T; et al. (2009). „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”.Hepatogastroenterology.56(90): 547—50.PMID19579640.
- ^Isoda N; Eguchi Y; Nukaya H; et al. (2009). „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”.Hepatogastroenterology.56(90): 437—41.PMID19579616.
- ^Shimizu K; Watanabe S; Watanabe S; et al. (2009). „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”.Hepatogastroenterology.56(89): 240—4.PMID19453066.
Literatura
[уреди|уреди извор]- Chihara, G. et al.” Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom)”,Cancer Research (1970),30(11):2776-2781.
- Ina, K. et al. “Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy”,World Journal of Clinical Oncology (2011),2(10):339-343.
Spoljašnje veze
[уреди|уреди извор]
- Lentinaneffects (antitumor and others)